Strides Pharma Science Limited

BSE: 532531 NSE: STAR
Strides Pharma Science Limited - pharma in Thane, Maharashtra, India. FY 2026 financials and compliance.
CIN L24230MH1990PLC057062 Incorporated 28 June 1990 ROC Mumbai HQ Thane, Maharashtra, India
Active Listed - NSE: STAR · BSE: 532531 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹4,858.68 Cr
▲ 6.43% YoY
Computed EBITDA · FY 2026
₹1,076.01 Cr
▲ 24.89% YoY
Net profit · FY 2026
₹574.52 Cr
▼ 84.03% YoY
Authorised capital
₹218.37 Cr
Registered with MCA
Paid-up capital
₹92.17 Cr
Issued & subscribed
Open charges
₹1,830.26 Cr
Satisfied ₹11,468 Cr
Company age
36 yrs
Est. 1990
Employees · EPFO
2,152
Latest available

About Strides Pharma Science Limited

Data last updated: 14 July 2026

Strides Pharma Science Limited is a public limited company based in Thane, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 28 June 1990, the company has been in operation for over 36 years.

Registered with ROC Mumbai under CIN L24230MH1990PLC057062. Listed on BSE: 532531 and NSE: STAR.

Capital: an authorised share capital of ₹218.37 Cr and a paid-up capital of ₹92.17 Cr. Formerly known as Strides Pharma Sciences Limited and Strides Shasun Limited. It is led by directors including Arun Kumar Pillai and Kausalya Santhanam.

Last AGM: 07 August 2025. Financial statements filed for year ended 31 March 2025. Office: Sector 30, Thane, Maharashtra.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹4,858.68 Cr, a growth of 6.43% compared to the previous year. The net worth stands at ₹3,149.34 Cr (up 21.76% YoY). Total assets are valued at ₹6,927.23 Cr (up 14.52% YoY).

The company has a workforce of approximately 2,152 employees as per the latest available data. Its group structure includes 3 subsidiaries.

The company is associated with 1 brand - Strides Pharma Science. As per MCA filings, the company has open charges of ₹1,830.26 Cr and satisfied charges of ₹11,468 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website strides.com.

Company Details of Strides Pharma Science Limited
CIN L24230MH1990PLC057062
Registration Number 057062
Incorporation Date 28 June 1990
ROC Mumbai
Listing Status Listed (BSE: 532531, NSE: STAR)
Company Status Active
Date of Last AGM 07 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Badree Komandur Managing Director Aditya Arun Kumar Whole-Time Director Vikesh Kumar Cfo
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    strides.com
  • Social Media
  • Registered Address
    Cyber One Unit No. 902 Sector 30A, Plot No – 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703
  • Industry
    Pharma, Drug Formulation & Development
Company report
Strides Pharma Science Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Strides Pharma Science Limited report

Financials, compliance, directors, charges, ownership and filings for Strides Pharma Science Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Strides Pharma Science Limited

Strides Pharma Science Limited has undergone 7 name changes throughout its history. The current legal name is Strides Pharma Science Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Strides Pharma Science Limited Current
Strides Pharma Sciences Limited Previous
Strides Shasun Limited Previous
Strides Arcolab Limited Previous
Strides Pharma Limited Previous
Strides Pharmaceuticals Limited Previous
Strides Pharmaceuticals Private Limited Previous
Strides Limited Previous

Associated Brands with Strides Pharma Science Limited

Strides Pharma Science Limited operates one associated brand: Strides Pharma Science. These brands represent Strides Pharma Science Limited's diversified market presence and brand portfolio.

Brand Description Website
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured. strides.com

Business Activity of Strides Pharma Science Limited

Strides Pharma Science Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Strides Pharma Science Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Strides Pharma Science Limited

Strides Pharma Science Limited is audited by BSR & Co., LLP (ICAI peer reviewed, certificate valid till 2027-03-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
BSR & Co., LLP (ICAI peer reviewed, certificate valid till 2027-03-31) FY 2026 Declaration of unmodified opinion

Board of Directors and KMP of Strides Pharma Science Limited

Strides Pharma Science Limited currently reports 8 directors and 2 key managerial personnel. 19 former directors have served the organization.

Current Directors and KMP
Name Designation Appointment Date Tenure Status
Arun Kumar Pillai
Also directs: Chayadeep Ventures Llp, Agnus Capital Llp, Karuna Group Llp and 2 more
Director 05 Apr 2025 1 Years 4 Months Current
Kausalya Santhanam
Also directs: Solara Active Pharma Sciences Limited, Right Way Nutrition Llp, Synthix Global Pharma Solutions Limited and 1 more
Director 11 Dec 2019 6 Years 8 Months Current
Manjula Ramamurthy Company Secretary 03 Feb 2017 9 Years 6 Months Current
Badree Komandur Managing Director 18 May 2017 9 Years 2 Months Current
Homi Rustam Khusrokhan
Also directs: Neuland Laboratories Ltd., The Anglo Scottish Education Society
Director 18 May 2017 9 Years 2 Months Current
Mukta Malik Arora
Also directs: Astellas Pharma Capability Centre India Private Limited
Director 01 Feb 2025 1 Years 6 Months Current
Showing 6 of 10 current directors and KMP. View all directors and KMP

Financials of Strides Pharma Science Limited FY 2026 filings available

Strides Pharma Science Limited reported revenue of ₹4,858.68 Cr (up 6.43% YoY) for FY 2026.

Revenue · FY 2026
₹4,858.68 Cr ▲ 6.43%
Profit · FY 2026
₹574.52 Cr ▼ 84.03%
Computed EBITDA · FY 2026
₹1,076.01 Cr ▲ 24.89%
Revenue₹ Cr · Consolidated02,0004,0006,000FY 2020: ₹2,752 Cr2,752FY 2020FY 2021: ₹3,316 Cr · +20.5% YoY3,316+20.5%FY 2021FY 2022: ₹3,070 Cr · -7.4% YoY3,070-7.4%FY 2022FY 2023: ₹3,688 Cr · +20.1% YoY3,688+20.1%FY 2023FY 2024: ₹4,051 Cr · +9.8% YoY4,051+9.8%FY 2024FY 2025: ₹4,565 Cr · +12.7% YoY4,565+12.7%FY 2025FY 2026: ₹4,859 Cr · +6.4% YoY4,859+6.4%FY 2026
Net Profit₹ Cr · Consolidated-2,00002,0004,000FY 2020: ₹31 Cr30.6FY 2020FY 2021: ₹258 Cr · +742.8% YoY258+742.8%FY 2021FY 2022: ₹474 Cr (loss) · -284% YoY-474FY 2022FY 2023: ₹212 Cr (loss) · +55.2% YoY-212FY 2023FY 2024: ₹94 Cr (loss) · +55.6% YoY-94.3FY 2024FY 2025: ₹3,598 Cr · +3914.4% YoY3,598+3914.4%FY 2025FY 2026: ₹575 Cr · -84% YoY575-84%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year05001,0001,500Q1'25: ₹1,088 Cr · +16.9% YoY1,088+16.9%Q1'25Q2'25: ₹1,201 Cr · +20.2% YoY1,201+20.2%Q2'25Q3'25: ₹1,154 Cr · +11.2% YoY1,154+11.2%Q3'25Q4'25: ₹1,190 Cr · +9.8% YoY1,190+9.8%Q4'25Q1'26: ₹1,120 Cr · +3% YoY1,120+3%Q1'26Q2'26: ₹1,221 Cr · +1.6% YoY1,221+1.6%Q2'26Q3'26: ₹1,195 Cr · +3.6% YoY1,195+3.6%Q3'26Q4'26: ₹1,323 Cr · +11.2% YoY1,323+11.2%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹4,858.68 Cr ₹4,565.34 Cr ₹4,051.12 Cr ₹3,688.39 Cr ₹3,070.25 Cr ₹3,315.87 Cr ₹2,751.97 Cr
Other Income ₹150.71 Cr ₹58.72 Cr ₹39.7 Cr ₹90.33 Cr ₹131.99 Cr ₹51.43 Cr ₹53.11 Cr
Total Income ₹5,009.4 Cr ₹4,624.06 Cr ₹4,090.83 Cr ₹3,778.72 Cr ₹3,202.24 Cr ₹3,367.3 Cr ₹2,805.08 Cr
Cost of Materials Consumed ₹1,558.92 Cr ₹1,475.89 Cr ₹1,341.11 Cr ₹1,441.68 Cr ₹1,090.93 Cr ₹1,390.42 Cr ₹1,020.35 Cr
Purchases of Stock-in-Trade ₹361.54 Cr ₹688.08 Cr ₹283.45 Cr ₹187.87 Cr ₹316.11 Cr ₹296.08 Cr ₹146.94 Cr
Changes in Inventories ₹38.28 Cr -₹184.01 Cr ₹15.94 Cr -₹2.67 Cr ₹95.28 Cr -₹353.71 Cr -₹44.81 Cr
Employee Benefit Expense ₹928.96 Cr ₹862.76 Cr ₹751.13 Cr ₹732.02 Cr ₹646.91 Cr ₹550.15 Cr ₹442.56 Cr
Finance Costs ₹178.55 Cr ₹248.85 Cr ₹314.45 Cr ₹261.14 Cr ₹176.74 Cr ₹150.07 Cr ₹155.72 Cr
Depreciation & Amortisation ₹202.4 Cr ₹192.26 Cr ₹220.68 Cr ₹243.25 Cr ₹233.01 Cr ₹206.29 Cr ₹173.7 Cr
Other Expenses ₹1,045.7 Cr ₹919.8 Cr ₹916.23 Cr ₹899.3 Cr ₹941.13 Cr ₹798.1 Cr ₹671.03 Cr
Total Expenses ₹4,314.34 Cr ₹4,203.63 Cr ₹3,842.99 Cr ₹3,762.6 Cr ₹3,500.11 Cr ₹3,037.39 Cr ₹2,565.49 Cr
Profit Before Exceptional Items & Tax ₹695.06 Cr ₹420.42 Cr ₹247.84 Cr ₹16.12 Cr -₹297.88 Cr ₹329.91 Cr ₹239.59 Cr
Exceptional Items -₹26.84 Cr ₹64.66 Cr -₹189.05 Cr -₹17.03 Cr -₹243.83 Cr ₹43.35 Cr -₹77.68 Cr
Profit Before Tax ₹668.22 Cr ₹485.08 Cr ₹58.79 Cr -₹91.7 Lakh -₹541.7 Cr ₹373.26 Cr ₹161.91 Cr
Total Tax Expense ₹94.17 Cr ₹77.52 Cr ₹31.59 Cr -₹55.3 Cr -₹178.26 Cr ₹31.65 Cr ₹11.33 Cr
Net Profit ₹574.52 Cr ₹3,597.51 Cr -₹94.31 Cr -₹212.33 Cr -₹474.25 Cr ₹257.73 Cr ₹30.58 Cr
  attributable to Owners ₹556.19 Cr ₹3,593.46 Cr -₹70.61 Cr -₹202.64 Cr -₹460.21 Cr ₹268.44 Cr ₹36.38 Cr
  attributable to NCI ₹18.33 Cr ₹4.06 Cr -₹23.7 Cr -₹9.7 Cr -₹14.04 Cr -₹10.71 Cr -₹5.8 Cr
Other Comprehensive Income ₹44.02 Cr ₹149.81 Cr -₹54.7 Cr ₹7.92 Cr ₹49 Cr ₹16.56 Cr ₹37.07 Cr
Total Comprehensive Income ₹618.54 Cr ₹3,747.32 Cr -₹149.02 Cr -₹204.41 Cr -₹425.25 Cr ₹274.28 Cr ₹67.65 Cr
EBITDA (computed) ₹1,076.01 Cr ₹861.53 Cr ₹782.97 Cr ₹520.51 Cr ₹111.88 Cr ₹686.26 Cr ₹569.01 Cr
Basic EPS ₹60.34 ₹44.05 ₹-13.72 ₹-24.56 ₹-51.28 ₹28.40 ₹5.68
Diluted EPS ₹60.34 ₹44.05 ₹-13.72 ₹-24.56 ₹-51.28 ₹28.37 ₹5.68
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹6,927.23 Cr ₹6,048.73 Cr ₹5,839.76 Cr ₹6,638.42 Cr
Non-current Assets ₹3,313.89 Cr ₹2,949.81 Cr ₹2,870.76 Cr ₹3,395.06 Cr
Current Assets ₹3,612.79 Cr ₹3,098.91 Cr ₹2,969 Cr ₹3,135.25 Cr
Property, Plant & Equipment ₹992.43 Cr ₹880.69 Cr ₹878.67 Cr ₹1,324.29 Cr
Inventories ₹1,634.79 Cr ₹1,277.57 Cr ₹1,126.24 Cr ₹1,146.51 Cr
Trade Receivables ₹1,288.96 Cr ₹1,202.94 Cr ₹1,141.87 Cr ₹1,299.4 Cr
Cash & Equivalents ₹188.7 Cr ₹112.56 Cr ₹161.02 Cr ₹303.5 Cr
Equity (Net Worth) ₹3,149.34 Cr ₹2,586.46 Cr ₹2,071.71 Cr ₹2,172.88 Cr
Equity Share Capital ₹92.17 Cr ₹92.16 Cr ₹91.9 Cr ₹90.3 Cr
Borrowings (Non-current) ₹552.32 Cr ₹571.24 Cr ₹671.5 Cr ₹1,139.79 Cr
Borrowings (Current) ₹1,116.37 Cr ₹1,224.37 Cr ₹1,743.03 Cr ₹1,634.67 Cr
Total Debt (computed) ₹1,668.69 Cr ₹1,795.61 Cr ₹2,414.53 Cr ₹2,774.46 Cr
Current Liabilities ₹2,895.49 Cr ₹2,591.52 Cr ₹2,879.26 Cr ₹2,990.2 Cr
Total Liabilities ₹3,777.9 Cr ₹3,462.26 Cr ₹3,768.05 Cr ₹4,465.54 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹702.52 Cr ₹684.37 Cr ₹701.07 Cr ₹44.41 Cr -₹257.82 Cr
Investing Cash Flow -₹173.04 Cr -₹89.69 Cr -₹150.25 Cr ₹302.47 Cr -₹118.73 Cr
Financing Cash Flow -₹453.41 Cr -₹642.58 Cr -₹693.32 Cr -₹213.92 Cr ₹421.32 Cr
Capital Expenditure ₹422.94 Cr ₹242.5 Cr ₹118.15 Cr ₹94.94 Cr ₹143.38 Cr
Free Cash Flow (computed) ₹279.58 Cr ₹441.88 Cr ₹582.91 Cr -₹50.53 Cr -₹401.2 Cr
Dividends Paid ₹36.87 Cr ₹22.99 Cr ₹13.52 Cr ₹0 ₹22.43 Cr
Net Change in Cash ₹76.13 Cr -₹48.43 Cr -₹142.48 Cr ₹132.77 Cr ₹44.9 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹1,323.47 Cr ₹1,194.65 Cr ₹1,220.83 Cr ₹1,119.74 Cr ₹1,190.39 Cr ₹1,153.67 Cr ₹1,201.11 Cr ₹1,087.51 Cr ₹1,084.04 Cr ₹1,037.67 Cr ₹999.43 Cr ₹929.99 Cr
Other Income ₹8.13 Cr ₹106.86 Cr ₹27.14 Cr ₹8.58 Cr ₹11.98 Cr ₹5.62 Cr ₹28.41 Cr ₹12.72 Cr -₹13.55 Cr ₹8.75 Cr ₹35.85 Cr ₹8.65 Cr
Total Income ₹1,331.6 Cr ₹1,301.51 Cr ₹1,247.97 Cr ₹1,128.32 Cr ₹1,202.37 Cr ₹1,159.28 Cr ₹1,229.52 Cr ₹1,100.22 Cr ₹1,070.49 Cr ₹1,046.42 Cr ₹1,035.28 Cr ₹938.64 Cr
Cost of Materials Consumed ₹408.88 Cr ₹459.71 Cr ₹429.76 Cr ₹260.58 Cr ₹269.73 Cr ₹476.58 Cr ₹448.85 Cr ₹364.21 Cr ₹353.84 Cr ₹375.13 Cr ₹342.3 Cr ₹269.85 Cr
Purchases of Stock-in-Trade ₹127.45 Cr ₹71.38 Cr ₹41.8 Cr ₹120.91 Cr ₹231.6 Cr ₹133.77 Cr ₹55.33 Cr ₹79.44 Cr ₹112.64 Cr ₹50.66 Cr ₹63.64 Cr ₹56.5 Cr
Changes in Inventories -₹7.7 Lakh -₹68.14 Cr ₹43.71 Cr ₹62.79 Cr -₹2.36 Cr -₹130.23 Cr -₹6.26 Cr -₹23.21 Cr -₹50.25 Cr -₹4.55 Cr ₹12.15 Cr ₹58.6 Cr
Employee Benefit Expense ₹247.11 Cr ₹229.54 Cr ₹226.78 Cr ₹225.52 Cr ₹222.86 Cr ₹215.64 Cr ₹219.41 Cr ₹212.17 Cr ₹199.17 Cr ₹184.49 Cr ₹199.93 Cr ₹167.53 Cr
Finance Costs ₹41.58 Cr ₹43.38 Cr ₹46.13 Cr ₹47.46 Cr ₹50.32 Cr ₹52.18 Cr ₹82.15 Cr ₹80.39 Cr ₹80.16 Cr ₹79.28 Cr ₹78.59 Cr ₹76.42 Cr
Depreciation & Amortisation ₹53.25 Cr ₹50.62 Cr ₹49.64 Cr ₹48.89 Cr ₹48.86 Cr ₹48.42 Cr ₹50.52 Cr ₹48.59 Cr ₹49.76 Cr ₹51.23 Cr ₹60.11 Cr ₹59.59 Cr
Other Expenses ₹300.4 Cr ₹266.22 Cr ₹247.22 Cr ₹231.86 Cr ₹250.69 Cr ₹247.59 Cr ₹247.97 Cr ₹237.91 Cr ₹238.91 Cr ₹238.12 Cr ₹228.28 Cr ₹210.92 Cr
Total Expenses ₹1,178.59 Cr ₹1,052.7 Cr ₹1,085.03 Cr ₹998.01 Cr ₹1,071.71 Cr ₹1,043.96 Cr ₹1,097.98 Cr ₹999.51 Cr ₹984.22 Cr ₹974.37 Cr ₹984.99 Cr ₹899.41 Cr
Profit Before Exceptional Items & Tax ₹153.01 Cr ₹248.81 Cr ₹162.94 Cr ₹130.31 Cr ₹130.67 Cr ₹115.32 Cr ₹131.55 Cr ₹100.71 Cr ₹86.27 Cr ₹72.05 Cr ₹50.29 Cr ₹39.23 Cr
Exceptional Items -₹6.41 Cr -₹3.3 Cr -₹8.77 Cr -₹8.37 Cr -₹27.42 Cr -₹2.43 Cr -₹3.87 Cr -₹3.74 Cr -₹8.07 Cr -₹10.07 Cr -₹164.93 Cr -₹5.98 Cr
Profit Before Tax ₹146.6 Cr ₹245.51 Cr ₹154.17 Cr ₹121.94 Cr ₹103.25 Cr ₹112.89 Cr ₹127.67 Cr ₹96.98 Cr ₹78.2 Cr ₹61.99 Cr -₹114.64 Cr ₹33.25 Cr
Total Tax Expense ₹18.77 Cr ₹37.35 Cr ₹21.59 Cr ₹16.45 Cr ₹20.76 Cr ₹23.81 Cr ₹21.2 Cr ₹16.86 Cr ₹19.25 Cr ₹10.1 Cr -₹7.44 Cr ₹9.68 Cr
Net Profit ₹129.28 Cr ₹208.12 Cr ₹131.52 Cr ₹105.59 Cr ₹85.62 Cr ₹90.04 Cr ₹93.66 Cr ₹68.31 Cr ₹10.44 Cr ₹54.06 Cr -₹149.46 Cr -₹9.36 Cr
  attributable to Owners ₹126.94 Cr ₹202.11 Cr ₹127.53 Cr ₹99.61 Cr ₹82.19 Cr ₹87.95 Cr ₹93.23 Cr ₹70.2 Cr ₹18.18 Cr ₹49.67 Cr -₹131.34 Cr -₹7.11 Cr
  attributable to NCI ₹2.34 Cr ₹6.02 Cr ₹3.99 Cr ₹5.99 Cr ₹3.42 Cr ₹2.09 Cr ₹42.9 Lakh -₹1.89 Cr -₹7.73 Cr ₹4.39 Cr -₹18.11 Cr -₹2.25 Cr
Other Comprehensive Income ₹19.7 Cr ₹9.88 Cr -₹24.25 Cr ₹38.69 Cr ₹77.12 Cr ₹72.43 Cr ₹10.03 Cr -₹9.85 Cr -₹53.31 Cr ₹6.13 Cr -₹6.65 Cr -₹88.3 Lakh
Total Comprehensive Income ₹148.99 Cr ₹218 Cr ₹107.27 Cr ₹144.28 Cr ₹162.73 Cr ₹162.47 Cr ₹103.69 Cr ₹58.46 Cr -₹42.87 Cr ₹60.19 Cr -₹156.1 Cr -₹10.24 Cr
EBITDA (computed) ₹247.84 Cr ₹342.81 Cr ₹258.71 Cr ₹226.66 Cr ₹229.85 Cr ₹215.93 Cr ₹264.22 Cr ₹229.7 Cr ₹216.19 Cr ₹202.57 Cr ₹188.98 Cr ₹175.24 Cr
Basic EPS ₹13.77 ₹21.93 ₹13.84 ₹10.81 ₹8.92 ₹9.56 ₹10.14 ₹7.64 ₹1.97 ₹-0.49 ₹-14.54 ₹-0.79
Diluted EPS ₹13.77 ₹21.92 ₹13.84 ₹10.81 ₹8.92 ₹9.55 ₹10.12 ₹7.62 ₹1.97 ₹-0.49 ₹-14.54 ₹-0.79
Latest 12 quarters shown of 24 on record.
Segment · FY 2024 (annual) Revenue Result (PBIT) Assets Liabilities
Bio-pharmaceutical business ₹0 -₹121.94 Cr - -
Pharmaceutical business ₹4,051.12 Cr ₹319.44 Cr - -
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹2,180.14 Cr ₹2,139.42 Cr ₹2,153.26 Cr ₹1,854.5 Cr ₹1,979 Cr ₹1,857.57 Cr ₹1,674.15 Cr
Other Income ₹123.06 Cr ₹46.19 Cr ₹72.31 Cr ₹84.07 Cr ₹123.49 Cr ₹89 Cr ₹100.16 Cr
Total Income ₹2,303.2 Cr ₹2,185.61 Cr ₹2,225.56 Cr ₹1,938.56 Cr ₹2,102.49 Cr ₹1,946.56 Cr ₹1,774.31 Cr
Cost of Materials Consumed ₹1,019.6 Cr ₹1,048.11 Cr ₹1,072.63 Cr ₹1,020.1 Cr ₹935.42 Cr ₹1,050.1 Cr ₹848.34 Cr
Purchases of Stock-in-Trade ₹79.4 Cr ₹62.63 Cr ₹29.23 Cr ₹24.47 Cr ₹51.83 Cr ₹56.31 Cr ₹38.46 Cr
Changes in Inventories ₹11.02 Cr -₹27.2 Cr ₹4.62 Cr ₹21.04 Cr ₹114.26 Cr -₹117.53 Cr ₹1.18 Cr
Employee Benefit Expense ₹381.6 Cr ₹377.59 Cr ₹335.21 Cr ₹267.01 Cr ₹272.09 Cr ₹272.72 Cr ₹221.77 Cr
Finance Costs ₹113.77 Cr ₹145.91 Cr ₹167.93 Cr ₹138.68 Cr ₹74.24 Cr ₹65.34 Cr ₹66.71 Cr
Depreciation & Amortisation ₹91.24 Cr ₹84.61 Cr ₹84.67 Cr ₹93.62 Cr ₹104.37 Cr ₹99.34 Cr ₹91.63 Cr
Other Expenses ₹403.47 Cr ₹415.86 Cr ₹456.3 Cr ₹423.4 Cr ₹528.77 Cr ₹408.65 Cr ₹354.36 Cr
Total Expenses ₹2,100.1 Cr ₹2,107.5 Cr ₹2,150.58 Cr ₹1,988.32 Cr ₹2,080.98 Cr ₹1,834.93 Cr ₹1,622.45 Cr
Profit Before Exceptional Items & Tax ₹203.1 Cr ₹78.11 Cr ₹74.99 Cr -₹49.76 Cr ₹21.51 Cr ₹111.64 Cr ₹151.86 Cr
Exceptional Items ₹0 -₹2.7 Lakh -₹5.37 Cr -₹15 Cr ₹0 ₹0 ₹0
Profit Before Tax ₹203.1 Cr ₹78.08 Cr ₹69.62 Cr -₹64.76 Cr ₹21.51 Cr ₹111.64 Cr ₹151.86 Cr
Total Tax Expense ₹19.47 Cr ₹18.93 Cr ₹4.13 Cr -₹69.44 Cr -₹158.68 Cr ₹33.4 Cr ₹40.16 Cr
Net Profit ₹183.64 Cr ₹2,886.21 Cr ₹65.49 Cr ₹4.68 Cr ₹180.19 Cr ₹78.24 Cr ₹111.7 Cr
Other Comprehensive Income -₹56.69 Cr -₹3.15 Cr -₹12.8 Lakh ₹3.62 Cr -₹4.02 Cr ₹23.93 Cr -₹35.37 Cr
Total Comprehensive Income ₹126.95 Cr ₹2,883.06 Cr ₹65.36 Cr ₹8.3 Cr ₹176.17 Cr ₹102.17 Cr ₹76.33 Cr
EBITDA (computed) ₹408.11 Cr ₹308.63 Cr ₹327.58 Cr ₹182.54 Cr ₹200.12 Cr ₹276.32 Cr ₹310.2 Cr
Basic EPS ₹19.92 ₹6.43 ₹7.20 ₹0.52 ₹20.08 ₹8.73 ₹12.47
Diluted EPS ₹19.92 ₹6.43 ₹7.19 ₹0.52 ₹20.07 ₹8.72 ₹12.47
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹5,395.72 Cr ₹5,030.95 Cr ₹5,837.78 Cr ₹5,619.74 Cr
Non-current Assets ₹3,022.13 Cr ₹2,885.44 Cr ₹3,421.93 Cr ₹3,493.34 Cr
Current Assets ₹2,373.59 Cr ₹2,145.5 Cr ₹2,415.86 Cr ₹2,126.4 Cr
Property, Plant & Equipment ₹634.2 Cr ₹606.42 Cr ₹507.87 Cr ₹555.67 Cr
Inventories ₹580.27 Cr ₹431.71 Cr ₹470.18 Cr ₹490.76 Cr
Trade Receivables ₹1,521.28 Cr ₹1,452.93 Cr ₹1,508.51 Cr ₹1,307.78 Cr
Cash & Equivalents ₹16.17 Cr ₹6.33 Cr ₹92.71 Cr ₹82.11 Cr
Equity (Net Worth) ₹3,283.52 Cr ₹3,192.74 Cr ₹3,561.12 Cr ₹3,455.05 Cr
Equity Share Capital ₹92.17 Cr ₹92.16 Cr ₹91.9 Cr ₹90.3 Cr
Borrowings (Non-current) ₹173.25 Cr ₹127.37 Cr ₹196.99 Cr ₹284.74 Cr
Borrowings (Current) ₹974.89 Cr ₹1,028.88 Cr ₹1,397.19 Cr ₹1,064.46 Cr
Total Debt (computed) ₹1,148.14 Cr ₹1,156.25 Cr ₹1,594.18 Cr ₹1,349.2 Cr
Current Liabilities ₹1,840.07 Cr ₹1,629.61 Cr ₹1,995.3 Cr ₹1,796.83 Cr
Total Liabilities ₹2,112.2 Cr ₹1,838.21 Cr ₹2,276.66 Cr ₹2,164.69 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹277.85 Cr ₹421.48 Cr -₹35.76 Cr ₹241.74 Cr -₹282.69 Cr
Investing Cash Flow -₹69.07 Cr -₹137.59 Cr -₹61.27 Cr -₹182.58 Cr ₹18.78 Cr
Financing Cash Flow -₹198.93 Cr -₹370.32 Cr ₹107.62 Cr ₹10.82 Cr ₹250.73 Cr
Capital Expenditure ₹168.57 Cr ₹166.2 Cr ₹67.29 Cr ₹80.69 Cr ₹68.17 Cr
Free Cash Flow (computed) ₹109.27 Cr ₹255.28 Cr -₹103.05 Cr ₹161.05 Cr -₹350.86 Cr
Dividends Paid ₹36.87 Cr ₹22.99 Cr ₹13.55 Cr ₹0 ₹22.43 Cr
Net Change in Cash ₹9.84 Cr -₹86.42 Cr ₹10.6 Cr ₹69.98 Cr -₹13.18 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹605.74 Cr ₹553.63 Cr ₹522.15 Cr ₹498.62 Cr ₹555.96 Cr ₹550.92 Cr ₹609.96 Cr ₹554.75 Cr ₹617.63 Cr ₹520.02 Cr ₹540.29 Cr ₹475.32 Cr
Other Income ₹3.97 Cr ₹103.24 Cr ₹14.09 Cr ₹1.76 Cr ₹12.12 Cr ₹2.43 Cr ₹23.55 Cr ₹11.83 Cr ₹29.63 Cr ₹8.69 Cr ₹22.34 Cr ₹11.65 Cr
Total Income ₹609.71 Cr ₹656.88 Cr ₹536.24 Cr ₹500.37 Cr ₹568.08 Cr ₹553.35 Cr ₹633.5 Cr ₹566.58 Cr ₹647.27 Cr ₹528.7 Cr ₹562.63 Cr ₹486.97 Cr
Cost of Materials Consumed ₹297.46 Cr ₹255.5 Cr ₹255.66 Cr ₹210.98 Cr ₹268.29 Cr ₹295.26 Cr ₹301.91 Cr ₹253.77 Cr ₹266.45 Cr ₹302.14 Cr ₹288.94 Cr ₹215.1 Cr
Purchases of Stock-in-Trade ₹15.89 Cr ₹17.75 Cr ₹30.01 Cr ₹15.75 Cr ₹10.65 Cr ₹32.27 Cr ₹7.5 Cr ₹12.21 Cr ₹10.99 Cr ₹6.6 Cr ₹6.42 Cr ₹5.21 Cr
Changes in Inventories ₹10.9 Lakh -₹90.3 Lakh -₹3.65 Cr ₹15.46 Cr ₹3.3 Cr -₹47.96 Cr ₹6.14 Cr ₹13.45 Cr ₹34.09 Cr -₹36.59 Cr -₹2.43 Cr ₹9.55 Cr
Employee Benefit Expense ₹95.94 Cr ₹95.14 Cr ₹96.49 Cr ₹94.04 Cr ₹91.86 Cr ₹93.8 Cr ₹96.76 Cr ₹94.87 Cr ₹86.6 Cr ₹85.66 Cr ₹86.25 Cr ₹76.7 Cr
Finance Costs ₹26.66 Cr ₹27.25 Cr ₹29.41 Cr ₹30.45 Cr ₹29.36 Cr ₹34.21 Cr ₹50.15 Cr ₹46.88 Cr ₹46.77 Cr ₹44.47 Cr ₹40.07 Cr ₹36.63 Cr
Depreciation & Amortisation ₹25.19 Cr ₹22.4 Cr ₹21.51 Cr ₹22.14 Cr ₹22.37 Cr ₹20.92 Cr ₹21.98 Cr ₹20.32 Cr ₹20.81 Cr ₹21.06 Cr ₹21.34 Cr ₹21.46 Cr
Other Expenses ₹121.95 Cr ₹104.95 Cr ₹81.42 Cr ₹95.16 Cr ₹113.92 Cr ₹103.45 Cr ₹134.63 Cr ₹119.41 Cr ₹128.72 Cr ₹96.55 Cr ₹117.84 Cr ₹113.19 Cr
Total Expenses ₹583.2 Cr ₹522.07 Cr ₹510.86 Cr ₹483.97 Cr ₹539.76 Cr ₹531.95 Cr ₹619.06 Cr ₹560.92 Cr ₹594.41 Cr ₹519.89 Cr ₹558.43 Cr ₹477.84 Cr
Profit Before Exceptional Items & Tax ₹26.51 Cr ₹134.8 Cr ₹25.39 Cr ₹16.4 Cr ₹28.32 Cr ₹21.39 Cr ₹14.44 Cr ₹5.66 Cr ₹52.85 Cr ₹8.81 Cr ₹4.19 Cr ₹9.13 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 -₹1.7 Lakh -₹1 Lakh ₹0 -₹7.4 Lakh -₹5.29 Cr ₹0 ₹0
Profit Before Tax ₹26.51 Cr ₹134.8 Cr ₹25.39 Cr ₹16.4 Cr ₹28.32 Cr ₹21.38 Cr ₹14.43 Cr ₹5.66 Cr ₹52.78 Cr ₹3.52 Cr ₹4.19 Cr ₹9.13 Cr
Total Tax Expense ₹10.16 Cr ₹12.91 Cr -₹6.65 Cr ₹3.06 Cr ₹12.2 Cr ₹6.44 Cr -₹87.6 Lakh ₹1.75 Cr -₹88.6 Lakh ₹97.8 Lakh ₹2.91 Cr ₹1.13 Cr
Net Profit ₹16.35 Cr ₹121.9 Cr ₹32.04 Cr ₹13.35 Cr ₹16.13 Cr ₹14.94 Cr ₹15.31 Cr ₹3.92 Cr ₹53.66 Cr ₹2.54 Cr ₹1.28 Cr ₹8 Cr
Other Comprehensive Income -₹28.09 Cr -₹2.87 Cr -₹19.64 Cr -₹6.09 Cr -₹2.21 Cr ₹6.42 Cr -₹9.09 Cr ₹1.74 Cr -₹2.32 Cr -₹6.91 Cr ₹2.49 Cr ₹6.61 Cr
Total Comprehensive Income -₹11.74 Cr ₹119.02 Cr ₹12.4 Cr ₹7.26 Cr ₹13.92 Cr ₹21.36 Cr ₹6.22 Cr ₹5.66 Cr ₹51.35 Cr -₹4.36 Cr ₹3.77 Cr ₹14.61 Cr
EBITDA (computed) ₹78.36 Cr ₹184.44 Cr ₹76.32 Cr ₹68.99 Cr ₹80.05 Cr ₹76.53 Cr ₹86.58 Cr ₹72.86 Cr ₹120.43 Cr ₹74.34 Cr ₹65.61 Cr ₹67.21 Cr
Basic EPS ₹1.77 ₹13.22 ₹3.48 ₹1.45 ₹1.75 ₹1.62 ₹1.66 ₹0.43 ₹5.84 ₹0.28 ₹0.14 ₹0.89
Diluted EPS ₹1.77 ₹13.22 ₹3.48 ₹1.45 ₹1.75 ₹1.62 ₹1.66 ₹0.43 ₹5.83 ₹0.28 ₹0.14 ₹0.89
Latest 12 quarters shown of 24 on record.
Segment · FY 2024 (annual) Revenue Result (PBIT) Assets Liabilities
Bio-pharmaceutical business ₹0 ₹0 - -
Pharmaceutical business ₹2,153.26 Cr ₹237.55 Cr - -
Want more history and ratios?
You're viewing the latest exchange-filed financials for Strides Pharma Science Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Strides Pharma Science Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 27.91%, foreign institutional investors hold 28.68%, domestic institutional investors hold 14.45%, retail and other public shareholders hold 28.95% of Strides Pharma Science Limited. The company had 86,616 shareholders on record.

Promoters: 27.91%DII (Domestic Institutional): 14.45%FII (Foreign Institutional): 28.68%Retail & Others: 28.95%
Mar 2026
QUARTER
27.91% Promoters
14.45% DII (Domestic Institutional)
28.68% FII (Foreign Institutional)
28.95% Retail & Others
Promoter holding - history
Now 27.91% · Mar 2026High 31.36% · Dec 2017Low 25.84% · Sep 2024
24%26.3%28.5%30.8%33%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 31.06%Mar 2016: 31.14%Jun 2016: 31.14%Sep 2016: 31.14%Dec 2016: 31.14%Mar 2017: 31.09%Jun 2017: 31.12%Sep 2017: 31.12%Dec 2017: 31.36%Mar 2018: 31.36%Jun 2018: 31.34%Sep 2018: 30.79%Dec 2018: 30.79%Mar 2019: 31.24%Jun 2019: 31.24%Sep 2019: 31.28%Dec 2019: 31.28%Mar 2020: 31.28%Jun 2020: 29.71%Sep 2020: 29.69%Dec 2020: 29.69%Mar 2021: 29.67%Jun 2021: 29.62%Sep 2021: 29.60%Dec 2021: 29.60%Mar 2022: 30.60%Jun 2022: 30.37%Sep 2022: 31.07%Dec 2022: 30.89%Mar 2023: 28.27%Jun 2023: 28.07%Sep 2023: 27.78%Dec 2023: 27.39%Mar 2024: 25.88%Jun 2024: 25.86%Sep 2024: 25.84%Dec 2024: 26.82%Mar 2025: 28.30%Jun 2025: 28.30%Sep 2025: 27.86%Dec 2025: 27.86%Mar 2026: 27.91%31.36%25.84%27.91%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters27.91%27.86%27.86%28.30%28.30%26.82%
Public72.09%72.14%72.14%71.70%71.70%73.18%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters27.91%28.30%25.88%28.27%30.60%29.67%31.28%31.24%31.36%31.09%31.14%
Public72.09%71.70%74.12%71.73%69.40%70.33%68.73%68.76%68.64%68.91%68.86%
Promoter change (YoY, %pts)-0.39+2.42-2.39-2.33+0.93-1.61+0.04-0.12+0.27-0.05-

Board & Governance of Strides Pharma Science Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Strides Pharma Science Limited has 8 directors - 5 independent and 2 executive. The board is chaired by Arun Kumar Pillai.

DirectorPositionOn board sinceListed boards
Arun Kumar Pillai Non-Executive - Non Independent Director · Chairperson 1990-06-28 3
Homi R Khusrokhan Non-Executive - Independent Director 2017-05-18 2
Kausalya Santhanam Non-Executive - Independent Director 2019-12-11 2
Ameet Pratheapsinh Hariani Non-Executive - Independent Director 2024-02-01 5
Badree Komandur Executive Director · CEO-MD 2017-05-18 1
Subir Chakraborty Non-Executive - Independent Director 2024-06-01 2
Aditya Arun Kumar Executive Director 2024-06-01 1
Mukta Arora Non-Executive - Independent Director 2025-02-01 1
Board Committees
CommitteeMembers
Audit Committee Homi R Khusrokhan (Chairperson), Kausalya Santhanam, Ameet Pratheapsinh Hariani, Subir Chakraborty, Mukta Arora
Nomination and remuneration committee Ameet Pratheapsinh Hariani (Chairperson), Homi R Khusrokhan, Kausalya Santhanam, Subir Chakraborty, Mukta Arora, Arun Kumar Pillai
Stakeholders Relationship Committee Kausalya Santhanam (Chairperson), Arun Kumar Pillai, Ameet Pratheapsinh Hariani, Subir Chakraborty
Risk Management Committee Homi R Khusrokhan (Chairperson), Kausalya Santhanam, Badree Komandur, Ameet Pratheapsinh Hariani, Subir Chakraborty, Aditya Arun Kumar, Mukta Arora, Sormistha Gosh
Corporate Social Responsibility Committee Kausalya Santhanam (Chairperson), Homi R Khusrokhan, Arun Kumar Pillai, Aditya Arun Kumar

Group Structure of Strides Pharma Science Limited

Strides Pharma Science Limited has 3 subsidiary companies and 3 associated companies. This group structure data is as of FY 2023. The corporate group structure reflects Strides Pharma Science Limited's business expansion strategy and organizational complexity.

3
Subsidiary companies
3
Associated companies
Key Subsidiaries
Company Name CIN Shares Held

Showing major subsidiaries. Total: 3.

Charges & Borrowings of Strides Pharma Science Limited

Open charges
₹1,830.26 Cr
Satisfied charges
₹11,468 Cr
Breakdown by lending institutions
Others₹1,829.62 Cr
Hdfc Bank Limited₹0.64 Cr
Latest charge details
DateLenderAmountStatus
20 Oct 2023 Hdfc Bank Limited ₹64.39 Lakh Open
19 Jul 2016 Others ₹1,829.62 Cr Open
27 Mar 2025 Others ₹100 Cr Satisfied
10 Feb 2025 Karnataka Bank Ltd. ₹100 Cr Satisfied
26 Sep 2024 State Bank of India ₹510 Cr Satisfied

Total charge records: 274 View all charges

Employees and EPFO Compliance at Strides Pharma Science Limited

Strides Pharma Science Limited has a workforce of 2,152 employees as of Nov 19, 2024.

Employee count
2,152
Active EPFO establishments
3
Employee growth
1.94%
Premium access

Employee and EPFO history for Strides Pharma Science Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Strides Pharma Science Limited

Premium access

GST registrations and filing compliance for Strides Pharma Science Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Strides Pharma Science Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Strides Pharma Science Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Strides Pharma Science Limited

Premium access

MSME payment history for Strides Pharma Science Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Strides Pharma Science Limited

Premium access

Corporate group structure for Strides Pharma Science Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Strides Pharma Science Limited

Premium access

MCA filings and documents for Strides Pharma Science Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Strides Pharma Science Limited

Charges
15 May 2026
A charge with Others of Rs. 1,829.62 Cr registered on 19 Jul 2016 with Charge ID 100062848 was modified on 15 May 2026.
Charges
09 Nov 2025
A charge registered on 03 Nov 2020 via Charge ID 100389968 with Hdfc Bank Limited was fully satisfied on 09 Nov 2025.
Charges
27 Oct 2025
A charge registered on 19 Sep 2023 via Charge ID 100793392 with Others was fully satisfied on 27 Oct 2025.
Charges
30 Sep 2025
A charge registered on 10 Feb 2025 via Charge ID 101057359 with Karnataka Bank Ltd. was fully satisfied on 30 Sep 2025.
Charges
17 Sep 2025
A charge registered on 27 Mar 2025 via Charge ID 101075943 with Others was fully satisfied on 17 Sep 2025.
Activity
07 Aug 2025
Strides Pharma Science Limited last Annual general meeting of members was held on 07 Aug 2025 as per latest MCA records.

Recent News on Strides Pharma Science Limited

Teva Names R. Ananth CEO for API Business
08 Nov 2023 · Contract Pharma

Frequently Asked Questions about Strides Pharma Science Limited

Strides Pharma Science Limited is an active public limited company in the pharma sector based in Thane, Maharashtra, India. It was incorporated on 28 June 1990 (36+ years old) and is registered under CIN L24230MH1990PLC057062. Listed on BSE: 532531 and NSE: STAR. The company has 2,152 employees.

Strides Pharma Science Limited reported revenue of ₹4,858.68 Cr for FY 2026 (up 6.43% YoY) based on consolidated NSE filings.

The current directors and KMP of Strides Pharma Science Limited are:

The primary industry of Strides Pharma Science Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Strides Pharma Science Limited is listed on both BSE (code: 532531) and NSE (symbol: STAR).

Strides Pharma Science Limited can be reached at the registered office: Cyber One Unit No. 902 Sector 30A, Plot No – 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703, or through the website strides.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available